Use of a monoclonal antibody specific for activated endothelial cells to quantitate angiogenesis in vivo in zebrafish after drug treatment

Angiogenesis

Volumn 7, Issue 3, 2004, Pages 243-253

  Wen, Lin Seng ^a   Eng, Kurt ^a   Lee, Jenny ^b   McGrath, Patricia ^a  

^a Phylonix Pharmaceuticals Inc   (United States)

^b Oncogene Science   (United States)

Author keywords

Angiogenesis; EC specific monoclonal antibody; ELISA; Zebrafish

Indexed keywords

2 METHOXYESTRADIOL; 3 TYPE 1 REPEAT PEPTIDE FRAGMENT OF THROMBOSPONDIN 1; ANGIOGENESIS INHIBITOR; FLAVOPIRIDOL; GENISTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PHY V002; PACLITAXEL; PENICILLAMINE; PEPTIDE; SIMVASTATIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY SPECIFICITY; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VALIDATION PROCESS; ZEBRA FISH;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD VESSELS; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EMBRYO, NONMAMMALIAN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; NEOVASCULARIZATION, PHYSIOLOGIC; PENICILLAMINE; SIMVASTATIN; STAINING AND LABELING; ZEBRAFISH;

ANIMALIA; DANIO RERIO; RODENTIA;

EID: 12444341888     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-004-4181-7     Document Type: Article

References (38)

1. Shalaby F et al. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66.
2. Fouquet B et al. Vessel patterning in the embryo of the zebrafish: guidance by notochord. Dev Biol 1997; 183: 37-48.
3. Gehring M et al. The SCL gene specifies haemangioblast development form early mesoderm. EMBO J 1998; 17: 4029-4045.
4. Liao W et al. The zebrafish gene cloche acts upstream of a flk-1 homologue to regulate endothelial cell differentiation. Development 1997; 124: 381-389.
5. Lyons MS et al. Isolation of the zebrafish homologues for the tie-1 and tie-2 endothelium-specific receptor tyrosine kinases. Dev Dyn 1998; 212: 133-140.
6. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
7. Liang D et al. Cloning and characterization of vascular endothelial growth factor (VEGF) from zebrafish Danio rerio. Biochimica et Biophysica Acta 1998; 1397: 14-20.
8. Westerfield M. The Zebrafish Book: A Guide for the Laboratory use of Zebrafish. Eugene: The University of Oregon Press 1993.
9. Childs S et al. Patterning of angiogenesis in the zebrafish embryo. Development 2002; 129: 973-82.
10. Isogai S. Horiguchi M. and Weinstein BM. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev Biol 2001; 230: 278-301.
11. Shaheen RM et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59: 5412-6.
12. Mabjeesh N et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003 3(4): 363-75.
13. Mooberry S. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 2003; 6(6): 355-61.
14. Shang W, Konidari I, Schomberg D. 2-Methoxyestradiol an endogenous estradiol metabolite differentially inhibits granulosa and endothelial cell mitosis: a potential follicular antiangiogenic regulator. Biol Reprod 2001; 65: 622-7.
15. Tan A. and Swain S. Review of flavopiridol a cyclin-dependent kinase inhibitor as breast cancer therapy. Semin Oncol 2002; 29(3 Suppl 11): 77-85.
16. Zhai S et al. Flavopiridol a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002; 36(5): 905-11.
17. Albertsson P, Lennernas, Norrby K. Chemotherapy and antiangiogenesis: Drug-specific effects on microvessel sprouting. APMIS 2003; 111(11): 995-1003.
18. Klos K et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibiton of Akt than either treatment alone. Cancer 2003; 98(7): 1377-85.
19. Ng S, Figg W and Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 2004; 64: 821-4.
20. Buchler P et al. antiangiogenic activity of genistein in pancreatic carcinoma cell is mediated by the inhibition of hypoxia-inducible factor-1 and the down regulation of VEGF gene expression. Cancer 2004; 100(1): 201-10.
21. McDonnell C et al. Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model. J Surg Res 2004; 116(1): 19-23.
22. Pepper M et al. 8-prenylnaringenin a novel phytoestrogen inhibits angiogenesis in vitro and in vivo. J Cell Physiol 2004; 199(1): 98-107.
23. Miao WM. et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and-independent mechanisms. Cancer Res 2001; 61(21): 7830-9.
24. Brouet A et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001; 89: 866-73.
25. Kawasaki K et al. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol 2003; 23(16): 5726-37.
26. Pourati I et al. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003; 146(5): 876-81.
27. Weis MHC, Glassford A, Cooke J. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
28. Gilbertson-Beadling S et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 1995; 36(5): 418-24.
29. Klauber N et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57(1): 81-6.
30. Kohkichi H et al. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line. Cancer Chemother Pharmacol 2004; 53: 68-74.
31. Nishishita T, Lin P. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem 2004; 91(3): 584-93.
32. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002; 248(2): 307-18.
33. Motoike T et al. Universal GFP reporter for the study of vascular development. Genesis 2000; 28(2): 75-81.
34. Parker L et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 2004; 428: 754.
35. Willett CE et al. Ikaros expression as a marker for lymphoid progenitors during zebrafish development. Dev Dyn 2001; 222(4): 694-8.
36. Thompson MA et al. The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. Dev Biol 1998; 197: 248-69.
37. Gallo O et al. Correlation between nitric oxide and cyclooxygenase-2 pathway in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 2002; 299(4): 517-24.
38. Jozkowicz A et al. Genetic augumentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc Res 2001; 51(4): 773-83.